GB20-5A8-31,一种用于治疗炎症性肠道疾病的抗TL1A抗体
Yu Huang1, Qiongying You1, Tianqi Yao1
1Drug Discovery, Center for Research and Development, Kexing Biopharm Co., Ltd., Shenzhen, Guangdong, China.
一种新的抗体,GB20-5A8-31,向瘤坏死因子样联体1A (TL1A),显示出治疗炎症性肠病 (IBD) 的强大潜力. 临床前研究表明其有效性和有利于药物开发的特性.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 生物制药开发 生物制药开发
背景情况:
- 炎症性肠病 (IBD) 由于治疗失败而存在重大未满足的医疗需求.
- 瘤坏死因子样联体1A (TL1A) 是IBD病变发生的关键标.
研究的目的:
- 设计和评估新型抗TL1A抗体GB20-5A8-31,作为IBD的潜在治疗方法.
- 评估GB20-5A8-31.31的临床前疗效,药理动力学和可开发性.
主要方法:
- 开发一种高亲和度的抗TL1A抗体 (GB20-5A8-31).
- 在体外评估TL1A信号抑制.
- 在急性IBD的老鼠和小鼠模型中的体内评估.
- 药物动力学和生物物理特征.
主要成果:
- GB20-5A8-31显示对TL1A的超高亲和力和强大的体外抑制.
- 该抗体在临床前IBD模型中显示出显著的抗炎和抗纤维作用.
- 观察到具有延长半衰期和优秀的生物物理性质的有利药理动力学.
结论:
- GB20-5A8-31 是IBD的一个有前途的治疗候选者.
- 它的临床前疗效和可开发性支持进一步推进临床研究.
更多相关视频
08:37Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
